BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36157469)

  • 1. Pituitary carcinoma - case series and review of the literature.
    Du Four S; Van Der Veken J; Duerinck J; Vermeulen E; Andreescu CE; Bruneau M; Neyns B; Velthoven V; Velkeniers B
    Front Endocrinol (Lausanne); 2022; 13():968692. PubMed ID: 36157469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
    Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
    Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
    Strowd RE; Salvatori R; Laterra JJ
    J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.
    Dai C; Sun B; Guan S; Wang W; Liu H; Li Y; Zhang J; Kang J
    BMC Endocr Disord; 2021 Oct; 21(1):217. PubMed ID: 34715828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
    Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
    Padovan M; Cerretti G; Caccese M; Barbot M; Bergo E; Occhi G; Scaroni C; Lombardi G; Ceccato F
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):181-198. PubMed ID: 36876325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
    Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
    Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
    Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
    ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
    Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
    J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
    Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
    Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive pituitary tumors (PitNETs).
    Nishioka H
    Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
    Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
    World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.